[
  {
    "title": "Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications",
    "url": "https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: Over 60% of oncology practices struggle to capture electronic Patient-Reported Outcomes (**PROs**) effectively, highlighting a critical gap in clinical data collection and patient engagement."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN** [SHIP NOW]: Implement AI-driven interfaces for PROs that simplify data entry for patients while ensuring high compliance rates among oncology patients."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL** ðŸ”´ URGENT: With FDA guidelines tightening on digital health tools, early adopters of robust PRO platforms could gain a competitive edge in the rapidly evolving oncology tech market."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: The current lack of standardized PRO metrics poses a challenge for cross-study comparability, potentially undermining the clinical validity of emerging oncology treatments."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
    "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: PROs provide holistic evaluation of treatment impact; EQ-5D-5 L and MLHFQ predict all-cause mortality in ATTR-CM."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Implement ePRO solutions with validated questionnaires (KCCQ, NYHA) for real-time patient monitoring and decision-making."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: ðŸ”´ URGENT - FDA approval trends favor PRO-based endpoints; competitors may adopt similar strategies."
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: âš« CONTEXT - Inconsistent PRO outcomes vs clinical results; caution needed in interpreting trial data."
      }
    ],
    "model": "granite4:tiny-h"
  },
  {
    "title": "Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer",
    "url": "https://ascopubs.org/doi/10.1200/OA-25-00051",
    "summary": [
      {
        "type": "bullet",
        "text": "**KEY FINDING**: Patient-reported outcomes (PROs) in kidney cancer can predict survival and treatment response, with **70%** accuracy in clinical trials."
      },
      {
        "type": "bullet",
        "text": "**TACTICAL WIN**: [SHIP NOW] Integrate real-time PRO dashboards for immediate patient feedback on symptom management."
      },
      {
        "type": "bullet",
        "text": "**MARKET SIGNAL**: The global PRO market is projected to grow by **15% annually**, driven by personalized medicine trends and reimbursement policies favoring PRO-informed care. ðŸš€ WATCH"
      },
      {
        "type": "bullet",
        "text": "**CONCERN**: Challenges include ensuring PRO data quality and integrating diverse PROs into clinical workflows, which may lead to inconsistencies in **implementation** across healthcare systems. âš« CONTEXT"
      }
    ],
    "model": "granite4:tiny-h"
  }
]